论文部分内容阅读
本文首次报告５０例ＥＢ病毒ＶＣＡ－ＩｇＡ抗体阴性鼻咽癌病人的临床特征及远期疗效。５０例病人中，颈淋巴阴性（Ｎｏ）病人占５８％（２９／５０）其中Ｔ１－２ＮｏＭｏ病人１９例。本组病人５年生存率６６％，１０年生存率５４％．较高的生存率与Ｎｏ病例多有关。随着Ｎ分期的升级，生存率下降。Ｔ３－４ＮｏＭｏ病人给予较高剂量照射，其１０年生存率为３３．３％；Ｔ分期较早病人给予低剂量照射，也获得较高的生存率，提示不同了分期的病人需要不同的放射剂量。本文还总结、讨论了此类病人的临床症状，抗体阴性可能原因及诊断方法。
This article first reported 50 cases of Epstein-Barr virus VCA-IgA antibody-negative patients with nasopharyngeal carcinoma clinical features and long-term efficacy. Of the 50 patients, 58% (29/50) had cervical lymphatic negative (No), and 19 had T1-2NoMo. This group of patients 5-year survival rate of 66%, 10-year survival rate of 54%. Higher survival rates are related to No cases. With the escalation of N staging, the survival rate decreased. T3-4NoMo patients given higher doses of irradiation, the 10-year survival rate was 33.3%; T stage earlier patients given low-dose irradiation, also obtained a higher survival rate, suggesting that different staging patients need different doses of radiation . This article also summarizes and discusses the clinical symptoms of such patients, the possible causes of antibody negative and diagnostic methods.